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The concept of hormesis has received consider-
able attention over the past several years
(Kaiser 2003a, 2003b). A recent literature
search in the PubMed database on the term
“hormesis” yielded 215 papers published
between 2000 and 2004 compared to 116
published in 1999 and earlier (PubMed 2005).
In several commentaries and reviews, horme-
sis—defined as low-dose stimulation, high-
dose inhibition—has been used to promote
the notion that low-level exposures to known
toxic chemicals could be “beneﬁcial” to human
health (Calabrese and Baldwin 2003c; Renner
2004). For example, it has been proposed that
if low-dose stimulatory responses were assumed to
be beneﬁcial, the decision maker could view horme-
sis as adding potential beneﬁt to society and could
estimate an optimized population-based exposure
standard. (Calabrese and Baldwin 2003a, p. 188)
Some proponents of this view claim hormesis
is an adaptive, broadly generalizable phenome-
non and argue that in the absence of contra-
dictory information, the default assumption
for risk assessments should be that at low expo-
sures, toxic chemicals induce stimulatory
effects (Calabrese and Baldwin 2003a). We
argue that many examples used to support the
widespread frequency of hormesis are better
described by the more general term “nonmo-
notonic” dose responses. Nonmonotonic is
used to describe dose–response relationships in
which the direction of a response changes with
increasing or decreasing dose. Use of the term
hormesis, with the associated descriptors of
low-dose stimulation and high-dose inhibition,
can only be justiﬁed if there is an understand-
ing of the biological processes underpinning
that specific dose response. We agree that
there is a need to address nonmonotonic
dose–response relationships in the risk assess-
ment process. However, even if certain low-
dose effects were sometimes determined to be
beneﬁcial, this ﬁnding should not be used to
influence regulatory decisions to increase
environmental exposures to toxic agents, given
factors such as variability in individual suscep-
tibility, variability in individual exposures, and
the public’s regular exposure to complex
mixtures. Our commentary focuses on the
evaluation of the hormesis hypothesis and con-
sequences of incorporating low-dose beneﬁcial
effects into public health decisions, with special
emphasis on the following issues: 
• The concept of hormesis is based largely on
empirical observations and does not adequately
consider underlying mechanism(s) of action.
Without an understanding of the mecha-
nisms underlying a hormetic response, it is
not appropriate to conclude that hormesis is
a uniformly adaptive phenomenon.
• Stimulatory responses are not always benefi-
cial, and some may be harmful. There is no
scientific support for the assumption that
stimulatory responses such as increased
growth, enzyme activity, hormone concen-
tration, and cell proliferation are beneﬁcial.
• Health decisions based on beneﬁcial effects must
address all the induced effects by that agent.
Examples cited to support the incorporation
of low-dose beneﬁcial effects into exposure
standards ignore other adverse effects that are
induced by different mechanisms and that
occur at similar or lower dose levels.
• Health decisions based on beneficial effects
must address interindividual differences
in exposure and susceptibility, including
genetic, life-stage, and health status factors.
Susceptibilities and exposure levels vary
among people over the course of a lifetime.
In many cases timing of exposure can be
more important than dose in determining
health outcomes. Fundamental physiological
differences stemming from genetic hetero-
geneity and differences in health status will
also inﬂuence susceptibility. 
• Health decisions based on beneﬁcial effects must
address the fact that other environmental and
workplace exposures may alter the low-dose
response of a single agent. Exposures in the real
world do not occur to single substances but
to mixtures of toxicants that can interact
with each other or affect different steps of
multistage disease processes. The mix of
chemicals that individuals are exposed to
varies depending on the nature of their work,
indoor home environment, drinking water
supply, food sources, school environment,
and where they socialize, in addition to
lifestyle choices such as diet, hobbies, hygiene
practices, and other factors such as the use of
prescription and over-the-counter drugs.
Moreover, many of these compounds can
affect the same target tissues by either similar
or different mechanisms of action. 
The Concept of Hormesis As an
Adaptive Response Does Not
Adequately Consider Underlying
Mechanisms of Action
As already stated, hormesis is generally
described as low-dose stimulation and high-
dose inhibition, producing a nonmonotonic
dose response. This may be visualized in the sit-
uation in which low-dose exposure to an agent
stimulates growth and high-dose exposure
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Hormesis (defined operationally as low-dose stimulation, high-dose inhibition) is often used to
promote the notion that while high-level exposures to toxic chemicals could be detrimental to
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cal processes. Even if certain low-dose effects were sometimes considered beneﬁcial, this should not
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2004). U- or J-shaped dose responses (Figure 1,
dashed line) can also be considered hormetic. A
more recent deﬁnition of hormesis by Calabrese
and co-workers considers the phenomenon to
be an “adaptive” and frequently observed
response resulting from exposure to a perturb-
ing agent (Calabrese and Baldwin 2002b).
Many of the recent publications on hormesis
and its application to risk assessment are co-
authored by Calabrese or reference his work.
Thus, the works of Calabrese and his colleagues
at the University of Massachusetts-Amherst are
cited frequently in this article. These authors
assert that
the hormetic phenomenon response is a common,
evolutionary-based strategy to carefully regulate
resource allocation in a deﬁnable range within the
context of the re-establishment and maintenance of
homeostasis. (Calabrese and Baldwin 2002a,
p. 333)
In general this deﬁnition has positive (i.e., bene-
ﬁcial) connotations in that it implies that by
adapting or coping with a stressor one will not
suffer ill consequences. Yet, the evaluation crite-
ria used to conclude that hormesis is a wide-
spread, adaptive phenomenon are based on
empirical observations of dose–response rela-
tionships with no regard for underlying mecha-
nism(s) (Calabrese and Baldwin 2001, 2003).
Calabrese and Baldwin attempted to
evaluate the frequency of hormesis by first
reviewing studies published in three journals
[Environmental Pollution (1970–1998),
Bulletin of Environmental Contamination and
Toxicology (1966–1998), and Life Sciences
(1962–1998)] that they believed to represent a
broad range of experimental models (Calabrese
and Baldwin 2001). Epidemiologic and ﬁeld
studies were excluded from this analysis, as
were non-English language articles. The
authors evaluated 668 dose–response relation-
ships from 195 published articles for evidence
of hormesis that met the following inclusion
criteria: a) presence of a concurrent control;
b) capacity to achieve responses greater than
(or less than) the control response; c) at least
two doses below the no observed adverse effect
level (NOAEL); and d) at least one dose show-
ing a priori criteria-based inhibition (Calabrese
and Baldwin 2001). The NOAEL was deﬁned
as either a) the highest dose with a response
not statistically different with respect to adverse
response from the control or b) the highest
dose with a response ≥ 90% of control for
inverted U-shaped dose–response relationship
or as the highest dose with a response ≤ 110%
of control for U- or J-shaped dose–response
relationships. A priori criteria-based inhibition
occurs when a) the response for at least one
dose higher than the NOAEL is statistically
different from controls, b) the response for at
least one dose higher than the NOAEL shows
a change of twice the value of the SD or SEM
compared to the control group (for studies
where only data distribution is reported); and
c) the response for at least two doses higher
than the NOAEL is < 90% of the control for
inverted U-shaped dose–response relationships
or > 110% of the control for U- or J-shaped
dose–response relationships.
A dose–response relationship was consid-
ered hormetic if a) at least one dose at or below
the NOAEL was statistically increased (for
inverted U-shaped dose–response relationships)
or decreased (for J- or U-shaped dose–response
relationships); b) at least three doses at or below
the study NOAEL had responses ≥110% of the
control (for inverted U-shaped dose–response
relationships) or ≤ 90% of the control (for J- or
U-shaped dose–response relationships); or c) for
studies in which only data distribution is
reported, variability in response (2 times the SD
or SEM) did not overlap with variability in the
control group.
Using a study NOAEL to determine
whether there are stimulatory effects at or
below that dose is problematic because the
determination of a NOAEL whether by select-
ing one of the actual doses in a study (non-
significant change from control) or by
modeling the dose–response data is inﬂuenced
by the variability in the experimental data,
sample size, the statistical power of the study,
the end point being evaluated, the duration
and route of exposure, and so forth. Because
of variability in the control response (reﬂected
in historical control data), a difference in
response between the current control group
and the dose groups below the presumed
NOAEL may give the false appearance of a
hormetic response. Thus, in some cases an
apparent hormetic response may simply reﬂect
data variability (Figure 2) rather than low-dose
stimulation and high-dose inhibition.
The evaluation criteria used by Calabrese
and Baldwin to determine whether a dose
response is hormetic do not require statisti-
cally signiﬁcant changes from control. Many
of the dose responses classified as hormetic
were identified based on the criteria that at
least three doses at or below a study NOAEL
differ by ≥ 10% of the relative control
response (Calabrese and Baldwin 2001). For
example, a change in incidence from 20 of
100 (20%) to 18 of 100 (18%) would be
interpreted as a 10% change from control
response [(20–18) of 20] and not a 2% change
(20–18) in response. This approach can lead
to a large change relative to the control with
only a one-count change in response (e.g., the
difference between 3 of 20 and 2 of 20 would
amount to a 33% change). In this manner
even small changes in incidence that reflect
data variability would be interpreted incor-
rectly as evidence to support the widespread
occurrence of hormesis.
In some cases the apparent hormetic
response reported in animal studies may be
largely an artifact of the evaluation method-
ologies. For example, 2,3,7,8-tetrachloro-
p-dibenzodioxin (TCDD) has been frequently
cited as an environmental carcinogen that pro-
duces low-dose beneficial effects (Calabrese
and Baldwin 2003c; Kaiser 2003). In the car-
cinogenicity study of TCDD (Kociba et al.
1978), the incidence of tumors of the liver,
lung, tongue, and nasal turbinates were
increased, and the incidence of tumors of the
pituitary, uterus, mammary glands, pancreas,
and adrenal gland were decreased. In no case
was an individual tumor response nonmono-
tonic; however, by calculating the total num-
ber of tumors, Calabrese presents the overall
tumor response as hormetic (Kaiser 2003b).
We argue that this should not be considered
hormesis because none of the specific tumor
responses contributing to the shape of the
total tumor dose response can be considered
Thayer et al.
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Figure 1. Nonmonotonic dose response for growth
or cancer incidence.
Figure 2. An apparent hormetic response may
reﬂect data variability. Some responses may appear
to be hormetic but actually be an artifact of the
experimental and analytical methodology because
of data variability (shown here), small group size,
large number of end points analyzed, unequal evalu-
ations in all dose groups, effects of the agent on
body weight and survival, and the underlying mech-
anism of the nonmonotonic dose response. Criteria
for listing a response as hormesis must address all
these potential confounding factors.hormetic or nonmonotonic. A simpliﬁed ver-
sion of this scenario is presented in Figure 3.
There are additional issues regarding the
interpretation of the dose–response data for
total tumor incidence in the TCDD study. In
that study (Kociba et al. 1978), mortality was
increased in the high-dose group, and body
weights were decreased relative to that of con-
trols. Because adjustments were not made for
early mortality, estimations of total tumor rates
relative to controls are not reliable. In addition,
it is well known that lower body weight is asso-
ciated with reduced tumor incidence at several
sites (Rao et al. 1987). Further, histologic
examinations in the low-dose and mid-dose
groups were not as extensive as those per-
formed for the control and high-dose groups.
Thus, the apparent hormetic response is not
based on reliable data.
Stimulatory Responses Are
Not Always Beneﬁcial, and
Some May Be Harmful
Although Calabrese and Baldwin (2002b)
state that the adaptive response should not be
interpreted a priori as being either beneﬁcial
or harmful, in other publications they claim
that dose stimulatory responses are generally
beneﬁcial. For example:
Acceptance of hormesis will be difﬁcult, therefore,
because agencies will need to accept the possibility
(actually, the likelihood) that toxic substances, even
the most highly toxic (e.g., cadmium, lead, mer-
cury, dioxin, PCBs, etc.) can cause beneﬁcial effects
at low doses [emphasis added]. (Calabrese and
Baldwin 2003a, p. 191)
In any case, adaptive responses may be
beneficial or harmful depending on the life
stage or circumstances under which they
occur. For example, natural hormones are
responsible for maintaining homeostasis and
controlling normal development; hence,
exposure to agents that interfere with homeo-
static control processes, especially those that
stimulate growth at inappropriate or vulnera-
ble times, can lead to abnormal development.
The concept of hormesis is based on exper-
imental observations, but the assumption that
stimulatory effects are always or usually beneﬁ-
cial is unproven. Many low-dose stimulatory
responses with equally likely adverse conse-
quences include increased cell replication,
DNA synthesis; blood pressure, heart rate,
interleukin-2 release, prolactin release, testos-
terone concentration, luteinizing hormone
concentration, and dopamine outflow
(Calabrese and Baldwin 2003b).
The concept of radiation hormesis is based
on the hypothesis that low-dose ionizing radia-
tion induces adaptive responses that enhance
the repair of DNA damage from endogenous
and exogenous sources and stimulate cell
removal (Pollycove and Feinendegen 2003).
However, this hypothesis needs to be tested. In
addition, it is necessary to recognize that adap-
tive stress responses such as enhanced cell death
may be beneﬁcial or harmful depending on the
circumstance of the response, and interpreta-
tions of hormetic effects of radiation exposure
may be influenced by experimental designs.
For example, the report of a negative correla-
tion between domestic radon exposure and
lung cancer mortality (Cohen 1995) was likely
due to failure to account for confounding by
cigarette smoking (Puskin 2003). Moreover,
two recent reports refute the credibility of
“radiation hormesis” by concluding that low
doses of radiation present a cancer risk
[National Research Council (NRC) 2005;
International Agency for Research on Cancer
2005]. Regarding the possibility of low dose
beneﬁcial effects, the NRC concluded that 
the assumption that any stimulatory hormetic
effects from low doses of ionizing radiation will
have a significant health benefit to humans that
exceeds potential detrimental effects from the radia-
tion exposure is unwarranted. (NRC 2005, p. 585)
Studies reviewed in support of the radiation
hormesis hypothesis were “found either to be
based on ecologic studies or to cite ﬁndings not
representative of the overall body of data”
(NRC 2005, p 19).
There are other clear examples where a
stimulatory effect would not be considered
beneficial. For example, agents that induce
cytochrome P450 activities to enhance the rate
of elimination of xenobiotics will also increase
the mutagenic potential of chemicals that are
activated to DNA-reactive intermediates by
these enzymes. Glutathione S-transferase
(GST) is usually considered to be a detoxifying
enzyme. However, GST-mediated glutathione
conjugation of trichloroethylene and other
haloalkenes produces mutagenic intermediates.
Thus, in some cases increased GST activity
may be beneﬁcial while in other cases it may be
harmful. Polymorphisms in genes coding for
metabolizing enzymes contribute to interindi-
vidual variability discussed below and may vary
by more than 50-fold in humans (Guengerich
et al. 1991).
In utero exposure to low and high doses of
the synthetic estrogen diethylstilbestrol (DES)
has opposite effects on uterine response to
hormonal stimulation in adulthood (Alworth
et al. 2002). Although at low doses the effect is
stimulatory (increased uterine size) and there-
fore fits within the original definition of
hormesis, this effect is not beneﬁcial. In fact, a
chemically induced positive uterotropic
response is used as a screen for estrogenicity
and raises concern about the toxicity of the
agent [U.S. Environmental Protection Agency
(EPA) 1998].
Health Decisions Based 
on Beneﬁcial Effects Must
Address All Induced Effects 
The idea of focusing primarily on purported
beneficial hormetic responses when making
decisions for exposure standards is greatly
weakened when all the toxicologic and epi-
demiologic evidence for a given compound or
agent is considered. A major concern is that an
agent may produce an apparent low-dose
beneficial response for one effect but also
induce an adverse effect at that same dose in a
different organ or another species (Figure 4).
For example, cadmium has been touted as a
model hormetic agent (Calabrese and Baldwin
2003c), partly because low experimental doses
(1–10 µmol/kg) have been associated with-
nonstatistically signiﬁcant decreases in testicu-
lar tumors in rats (Waalkes et al. 1988).
However, a signiﬁcant increase in the incidence
Flaws of hormesis for public health decisions
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decrease in pituitary tumors.of prostatic neoplasias and an increase in the
number of prostate tumors per animal were
observed in this same study within the
hormetic dose range (Waalkes et al. 1988,
1997). Notably, cadmium has been long rec-
ognized as being carcinogenic to humans, asso-
ciated with prostate, lung, renal, and bladder
cancers (National Toxicology Program 2002).
Moreover, three epidemiologic studies
indicate that current exposures to cadmium in
the general population are associated with
adverse health outcomes (Matsuda et al. 2002;
Satarug and Moore 2004; Schwartz et al.
2003). One of the studies reported that
increasing levels of urinary cadmium are associ-
ated with impaired fasting glucose (pre-
diabetes) and diabetes after adjusting for age,
ethnicity, sex, and body mass index in a sample
of more than 8,700 adults (Schwartz et al.
2003). These findings are consistent with
animal data showing that cadmium causes
damage to the pancreas and alters glucose regu-
lation in laboratory animals (Han et al. 2003;
Kanter et al. 2003; Merali and Singhal 1980).
Cadmium and many other heavy metals are
also fundamentally toxic to the kidneys, with
chronic low-level exposure leading to tubular
damage (Goyer 1991). This damage is associ-
ated with increased mortality (standardized
mortality ratios) in areas such as Jinzu, Japan
(Matsuda et al. 2002). Among individuals with
limited kidney function and among many
elderly people whose kidney function declines
as they age, exposure to cadmium and other
nephrotoxins, even at very low levels, can prove
extremely dangerous. When all these ﬁndings
are considered, it is improbable that allowing
higher levels of cadmium in the environment
would provide an overall health beneﬁt for the
general population. 
Other purported hormetic agents such as
radiation present the same concern. Noncancer
health concerns include decreased birth weight
(Hujoel et al. 2004) and cognitive impairment
after prenatal radiation exposure (Hall et al.
2004; Otake and Schull 1998; Yamazaki and
Schull 1990).
Health Decisions Must Address
Interindividual Differences in
Exposure and Susceptibility
Regulating to achieve a purported beneficial
response would require standards to be set at a
speciﬁed level rather than below an exposure
level. This would require that exposure levels
in the general population be maintained within
a narrow window which would be impossible.
Even at a given environmental standard, dif-
ferences in body mass can result in signiﬁcant
differences in exposure. For example, on a
body-weight basis compared to adults, children
breathe 3 times as much air, drink up to
7 times as much water, and ingest 3 times as
much dust and soil because they put their
hands in their mouths frequently (U.S. EPA
1997, 2002). The National Academy of
Sciences Committee on Pesticides emphasized
the importance of exposure in accounting for
the differences in pesticide-related health risks
between children and adults (National
Academy of Sciences 1993). 
Susceptibilities vary among individuals and
over the course of a lifetime, making it difﬁcult
to identify a beneﬁcial hormetic exposure at the
population level. Based on numerous intrinsic
and extrinsic factors that affect interindividual
susceptibility to toxic agents, a dose that may
appear to be beneﬁcial for one subgroup (e.g.,
healthy young males) may produce adverse
health effects in other subgroups (e.g., children,
the elderly, immune-compromised individuals,
or workers exposed to other toxic agents;
Figures 5 and 6). 
Consider ethanol, which is cited as a classic
hormetic agent because low or moderate drink-
ing is associated with beneficial outcomes
including reduced overall mortality and
reduced risk of coronary heart disease (CHD)
and stroke, whereas high consumption is asso-
ciated with other types of heart diseases, neuro-
logical disorders, cancer, liver cirrhosis, and
traffic accidents (Agarwal 2002). But low to
moderate drinking in pregnant women
(deﬁned as 1.2–2.2 drinks per day) is discour-
aged because even small amounts of alcohol
during pregnancy (0.5 drinks per day) have
been associated with adverse behavioral out-
comes in children, including aggressive behav-
ior (Sood et al. 2001). Because no evidence
exists for thresholds of risk-free drinking dur-
ing pregnancy, the American Academy of
Pediatrics and the American College of
Obstetrics and Gynecologists recommend
abstinence for preconceptional and pregnant
women (Sokol et al. 2003). Health decisions
based on a limited characterization of variabil-
ity in hormetic responses among exposed indi-
viduals may result in excessive health risks for
susceptible subpopulations who do not experi-
ence the same dose-related effects. 
A recent analysis of experimental animal
studies for four types of ionizing radiation
(Cs-137 gamma rays, X rays, neutrons, and
internal β rays resulting from the injection of
tritiated water) estimated a 3.5- to 5.3-fold
increase in carcinogenic sensitivity per dose
when exposure occurred in the fetal to birth–
weaning period relative to comparable doses in
adults (Hattis et al. 2004). In addition to
lifestage differences in susceptibility to radia-
tion-induced cancer, tumor response to radia-
tion in adult animals varies depending on strain
(Broerse et al. 1986), hormone status (i.e.,
estrogen levels; Bartstra et al. 2000), and
whether the dose of radiation is a single or frac-
tionated exposure (Maisin et al. 1988). There
are many reasons that fetuses, infants, and chil-
dren are more sensitive to chemicals than are
adults. These range from the well-known sus-
ceptibilities of developing organ systems, such
as the nervous system to neurotoxins including
lead (Agency for Toxic Substances and Disease
Registry 1999) and mercury (NRC 2000), as
well as to age-related differences in metabolism
and elimination (Ginsberg et al. 2002).
In addition to differences in exposure, age
and genetic variabilities are relevant to consid-
eration of the toxicity of organophosophate
(OP) pesticides that are present in food and
pet treatments. The enzyme paraoxonase
(PON) metabolizes toxic breakdown products
of OPs. People with higher than average PON
levels due to genetic polymorphisms metabo-
lize OPs more quickly (Hulla et al. 1999).
Infants are especially vulnerable to OPs
because adult levels of PON are not produced
Thayer et al.
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Figure 5. Interindividual variability. An apparent maxi-
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Figure 6. Life stage differences in susceptibility. If
the fetus, children, elderly, or other groups do not
experience a beneﬁcial hormetic response, health
decisions based on hormesis will result in higher
risks for these populations.
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Fetus, children,
elderlyuntil approximately 2 years of age (Chen et al.
2003; Ecobichon and Stephens 1973). Other
exposures such as alcohol, cigarette smoke,
and certain medications also affect the level of
PON-1 activity (Gouedard et al. 2003; Wang
et al. 2004). Similarly, OP detoxification by
malaoxonase differs between adults and chil-
dren and varies at least 7-fold among adults
(Sams and Mason 1999). Health decisions
that do not adequately account for human
variability will not sufﬁciently protect vulnera-
ble segments of the general population.
Health Decisions Must Address
Other Environmental and
Workplace Exposures
Advocates of incorporating beneﬁcial hormetic
responses into risk assessment fail to recognize
that people are exposed to hundreds of com-
pounds each day, and these vary depending on
our environmental and occupational expo-
sures. According to Calabrese, maximal low-
dose hormetic response stimulation for a given
chemical occurs on average at a dose 5-fold
below the NOAEL (Renner 2004). Thus, it
follows that simultaneous exposure to other
compounds that elicit similar toxic responses
would be enough to move an individual from
the low-dose supposed beneﬁcial range to the
range where adverse effects are expected
(Figure 7). For example, a decision based on
an apparent low-dose beneficial effect for
TCDD would increase health risks because
the general population is exposed to numerous
dioxin-like compounds that also induce dis-
ease through activation of the aryl hydro-
carbon receptor. Given that residues of
hundreds of chemicals have been measured in
humans (3M 2002; Centers for Disease
Control and Prevention 2003; Environmental
Working Group 2003; Olsen et al. 2002;
Schecter et al. 2003), with many of them
affecting the same tissues and fluctuating in
concentration over the course of a lifetime,
titrating exposure to achieve a relatively nar-
row beneﬁcial hormetic range is untenable and
clearly a poor public health policy.
Conclusions
Only after careful consideration of the biologi-
cal underpinnings of a truly beneﬁcial response
can an exposure be considered for the general
population, such as the addition of folic acid to
cereals. If a toxic or hazardous pollutant were
found to have truly beneficial effects at low
dose, then that agent should be tested clini-
cally, go through the U.S. Food and Drug
Administration (FDA) approval process, and
be regulated as a pharmaceutical for those who
might beneﬁt from its use. Certainly, the gen-
eral population should not be exposed to
chemotherapeutic agents that benefit cancer
patients. For pharmaceuticals, it is understood
that there are trade offs between beneﬁts and
risks. For example, although aspirin is a gener-
ally well-tolerated pain reliever and is increas-
ingly advocated as a preventative tool for heart
attacks and colorectal cancer (Vainio and
Miller 2003; Werner et al. 2004), it is also
linked to increased risk of gastrointestinal
bleeding, cerebral hemorrhage (Werner et al.
2004), and asthma attacks (Jenkins et al.
2004). In addition, aspirin is not recom-
mended for children or teenagers who have or
are recovering from chicken pox or flulike
symptoms because it can cause debilitating and
sometimes lethal Reyes syndrome (U.S. FDA
2003). Individual risks to pharmaceutical
agents can be controlled with proper usage;
however, increased exposure to environmental
toxins presents additional involuntary risks for
the general population. Under the latter condi-
tion, exposure is inadequately controlled, and
there is no mechanism to correct for individual
circumstances (e.g., medical condition or age)
that may result in harm.
Although hormetic effects may occur in
some instances, it is indeed rare that exposures
to toxic, mutagenic, teratogenic, and carcino-
genic chemicals, even at low exposure levels,
would be risk free and provide health beneﬁts
for the general public. Portraying chemicals
with numerous adverse effects as having bene-
ﬁts while ignoring their hazards is irresponsible
and does not provide full and objective disclo-
sure. In the 1950s doctors prescribed DES to
pregnant women to prevent miscarriage and
premature births and to produce “bigger and
stronger babies” even though DES had been
shown to cause damage to reproductive tissues
in animals (Dinusson et al. 1948; Dunn and
Green 1963; Takasugi and Bern 1964).
Human use of DES was banned in the United
States in 1971 after the discovery of high rates
of rare, clear-cell adenocarcinomas of the
vagina and cervix in DES-exposed daughters
(Herbst 1981), and later studies showed ele-
vated breast cancer risk in women who took
DES during pregnancy (Titus-Ernstoff et al.
2001). Certainly, health policy decisions
should be based on scientific evidence and
not on speculation of health beneﬁts in order
for the general population to avoid repeating
the mistakes of the past similar to that of the
DES tragedy. 
The claims and projections of health bene-
ﬁts from exposures to environmental toxicants
and carcinogens are based on untested assump-
tions and disregard numerous well-established
scientific principles that underpin a public
health–protective approach to regulating expo-
sure to toxic substances. If hormesis were used
in the decision-making process to allow higher
exposures to toxic and carcinogenic agents, this
would substantially increase health risks for
many, if not most, segments of the general
population. 
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